Effects of CYP3A4 and P-glycoprotein inhibition or induction on the pharmacokinetics of ubrogepant in healthy adults: Two phase 1, open-label, fixed-sequence, single-center, crossover trials

• Main Authors: Abhijeet Jakate (Author), Ramesh Boinpally (Author), Matthew Butler (Author), Wendy Ankrom (Author), Marissa F Dockendorf (Author), Antonia Periclou (Author)
• Format: Book
• Published: SAGE Publishing, 2021-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: Ubrogepant is metabolized by cytochrome P450 3A4 (CYP3A4) and is a P-glycoprotein (P-gp) substrate. Objective: To assess effects of multiple-dose moderate-strong CYP3A4 and strong P-gp inhibitors and inducers on ubrogepant pharmacokinetic (PK) parameters. Methods: Two phase 1, open-label...